RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Where'd These Longs Go?Agreed, the shorts have made very good money on this one. CXR is still very undervalued as is specialty Pharma. CXR should be trading in the mid $40's U.S. On a fundamental basis. Takeout scenarios gets you to $55 to $65 U.S. They figures should grow by $1.50 U.S. Per quarter as the company generates free cash flow.